Further, SMOi modulates TGF-β and MAPK signaling in MPN and ameliorates the severe phenotype (i.e., splenomegaly and BM fibrosis) in JAK2V617F mice and support the rational development of SMO and JAK inhibitor combinations in MPN. Here, TGFB1 is linked to myeloproliferative disorder.